SecBot SecBot
8-K ·Filed Apr 22, 2026

ACONW

Aclarion, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001683168-26-003124
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor future 10-Q filings for actual repurchase activity and its impact on cash levels and share count; the program signals management's confidence in valuation but is not a guaranteed capital return.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
ACONW ▼ -36.52% at T+60d
NEUTRAL call -36.52% · α vs SPY -41.30% · entry $0.0345 → $0.0219
Entry = T+0 close
Apr 22, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.39%
$0.0345
settled 6mo ago
T+5d
-6.09%
call -6.09% · α -6.14%
$0.0324
settled 6mo ago
T+20d
0.00%
call 0.00% · α -3.17%
$0.0345
settled 5mo ago
T+60d
-36.52%
call -36.52% · α -41.30%
$0.0219
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Aclarion, Inc. announced a $2.5 million share repurchase program authorized by its board, to be executed over the next 12 months using existing cash. The program is discretionary and does not obligate the company to buy any specific number of shares.

Key Facts

  • Aclarion authorized a $2.5 million share repurchase program.
  • The repurchase program will be funded using existing cash and cash equivalents.
  • As of March 31, 2026, the company had approximately $19.0 million in cash and cash equivalents.
  • The program does not require the company to buy any specific number of shares and may be suspended or modified at any time.

Financial Impact

$2.5 million in potential stock repurchases over 12 months, funded from existing cash reserves of $19.0 million

cashshares outstanding

Risk Factors

  • Repurchases are discretionary and may not occur if market or business conditions change.
  • Use of cash for buybacks could limit funds available for R&D or other strategic investments.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001683168-26-003124
Document: aclarion_ex9901.htm0001683168-26-003124
Document: 0001683168-26-003124-index-headers.html0001683168-26-003124
Document: 0001683168-26-003124-index.html0001683168-26-003124
Document: 0001683168-26-003124.txt0001683168-26-003124

US Market Status

Market Closed — Opens in 6h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 22, 2026